AMPATH

AMPATHFor several years, Celgene has worked with the Indiana University School of Medicine, Moi University Teaching and Referral Hospital in Eldoret, Kenya, and a consortium of North American academic health centers to deliver health services, conduct health research, and develop leaders in healthcare for both North America and Africa. The institutional collaborators are collectively named the Academic Model Providing Access to Healthcare (AMPATH).

In 2001, in the face of the deadliest pandemic in human history, the collaborators joined forces to create one of Africa’s largest, most comprehensive and effective HIV/AIDS control systems. Today, working with the Kenyan Ministry of Health and the United States government, AMPATH is currently in the process of implementing and strengthening a population health model within an AMPATH– Ministry of Health (MoH) collaboration to achieve healthcare equity and improve the health of low- income populations in Kenya and beyond.

Celgene’s support to the AMPATH Oncology Institute has enabled the creation of a successful multiple myeloma (MM) program, the first and only in Kenya. Achievements include:

  • Development of safety pamphlets and materials for both patients and healthcare professionals for MM in Kenya.
  • Diagnostic improvements that led to an increase from 5 patients diagnosed with MM in 2010 to 61 new patients in 2015. The expected number of new MM diagnoses in the country is about 800/year.
  • Approximately 100 MM patients seen during routine clinic follow-up visits in 2015.
  • AMPATH’s MM program is currently seeking IRB approval for a 5-year retrospective data- driven study to demonstrate the feasibility of MM care with comparable outcomes in a resource poor country to more advanced settings.

The AMPATH MM program conducts extensive patient and family education; it held 10 patient support group meetings over the course of 2015 and supported the care of 61 new patients with MM. The program has conducted multiple Continuing Medical Education (CME) programs on MM per quarter and has expanded its reach to 12 outreach sites and other sites in Western Kenya. Celgene has also supported the establishment of a robust Oncology Pharmacist-led MM pharmacovigilance program and funded IT support for the development of electronic medical records for the MM program with decision support.

In addition to the MM program, Celgene is also providing robust assistance to AMPATH’s pharmacy infrastructure and novel patient care strategies — including education for patients with hematologic disorders, pharmaceutical supply chain enhancement, physical infrastructure support, and the development of a pharmacy residency training program.